Are there peer‑reviewed clinical trials on MemoBlast or Memo Blast specifically?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
A review of the provided reporting finds multiple peer‑reviewed clinical trials and published trial results for Mesoblast cell‑therapy products (for example trials of rexlemestrocel‑L and remestemcel‑L), but no mention of any product or study named "MemoBlast" or "Memo Blast" in the supplied sources; therefore there is no evidence in this reporting that a peer‑reviewed clinical trial exists specifically for something called MemoBlast [1] [2] [3]. The documentation instead details Mesoblast’s registered trials, Phase 2/3 programs and peer‑reviewed publications for other product names and NCT identifiers [4] [2] [1].
1. What the question really asks: product name vs. evidence standard
The user’s query targets two precise points: whether a product named MemoBlast / Memo Blast exists in the clinical literature, and whether any peer‑reviewed clinical trials have been published about it; answering requires name‑level matching across trial registries and peer‑reviewed journals, not simply reporting on adjacent cell‑therapy programs with similar‑sounding names (the supplied sources predominantly document Mesoblast’s programs, not a product called MemoBlast) [1] [2].
2. What the supplied reporting actually documents — established Mesoblast trials
The supplied sources document multiple Mesoblast trials and peer‑reviewed trial results: for chronic low back pain Mesoblast’s rexlemestrocel‑L has an active Phase III program and a 36‑month randomized trial reported in the literature (clinical trial enrollment and Phase III activity described by Mesoblast and trial sites) [1] [2], and the DREAM‑HF Phase 3 results for a Mesoblast cell therapy were published in a major cardiovascular journal (JACC) and reported in industry coverage [3]. Additional Mesoblast trials (AMICI, MPC‑06‑ID, etc.) and trial registrations are referenced across the material [5] [6] [4].
3. Absence of "MemoBlast" in the provided sources — what that means and its limits
Across the supplied documents there is no instance of the name "MemoBlast" or "Memo Blast"; the materials repeatedly reference Mesoblast products (rexlemestrocel‑L, remestemcel‑L, Ryoncil, RepliCart, Revascor) and specific NCT trials, but none refer to a MemoBlast brand or investigational agent (examples: Phase III rexlemestrocel‑L enrollment, the AMICI intracoronary MPC trial, and a peer‑reviewed MSC trial in ARDS) [1] [5] [4]. That absence in this dataset does not prove the non‑existence of MemoBlast outside these documents, only that the provided reporting contains no evidence of peer‑reviewed clinical trials under that name.
4. How to close the gap: where peer‑reviewed trials would be found and next steps
Peer‑reviewed clinical trials would appear as journal articles and as registered trials with unique identifiers (NCT numbers) on trial registries; the supplied sources themselves reference registry entries and NCT identifiers for Mesoblast work [4] [2]. To conclusively determine whether MemoBlast has peer‑reviewed trials, a thorough search should be run across PubMed/PMC, major peer‑reviewed journals, and trial registries (ClinicalTrials.gov and equivalent) for the exact strings "MemoBlast" and "Memo Blast" and for any company or sponsor names linked to that product; the supplied reporting does not perform or record that exhaustive name‑indexed search and so cannot supply a definitive negative beyond its own content.
5. Bottom line and reporting recommendation
Based on the sources provided, there are peer‑reviewed clinical trials for Mesoblast’s cell‑therapy candidates but none of the supplied documents mention a product called MemoBlast or report peer‑reviewed trials under that name, so the answer from this dataset is: no evidence found for peer‑reviewed trials on MemoBlast/Memo Blast specifically [1] [2] [3]. For a conclusive determination, independent searches of bibliographic databases and trial registries for the exact product name and alternative spellings are required; if a claimed MemoBlast trial or publication is cited elsewhere, provide that citation for verification against registries and journal indexes.